New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
|
|
- Melvyn Matthews
- 5 years ago
- Views:
Transcription
1 New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia are symptoms that are thought to originate in the gastroduodenal region early satiation postprandial fullness epigastric pain burning IBS is characterized by abdominal pain and discomfort in association with altered bowel habits
2 Functional Dyspepsia Moayyadi P. Curr Opin Gastroenterol 2012, 28: Irritable Bowel Syndrome Ford A. Clin Gastroenterol Hepatol 2012;10
3 FD Pathophysiology Rapid or delayed gastric emptying Impaired gastric accommodation Hypersensitivity to gastric distention Altered response to duodenal lipids or acid H. Pylori infection Abnormal duodenojejunal motility Central nervous system dysfunction Tack, J. Gastroenterology 2004;127: IBS Physiologic Features Altered motility Visceral hyperalgesia Disturbance of brain-gut interaction Abnormal central processing Autonomic and hormonal events Intestinal microbiota Psychosocial disturbance
4 Subcategories of FD Post-prandial distress syndrome (PDS) Postprandial fullness and early satiation Respond to prokinetic agent Epigastric pain syndrome (EPS) Epigastric pain and burning Respond acid suppressive therapy Major overlap between PDS and EPS Gastroenterology 2006;130: Categories of IBS Diarrhea-predominant IBS (IBS-D) Loose (mushy) or watery stools > 25% of BMs Hard or lumpy stools < 25% BMs Constipation-predominant IBS (IBS-C) hard or lumpy stools > 25% of BMs loose (mushy) or watery stools < 25% BMs Mixed IBS (IBS-M) hard or lumpy stools > 25% of BMs loose (mushy) or watery stools > 25% of BMs Unsubtyped IBS
5 Normal Gastric Function Tack, J. Gastroenterology 2004;127: Functional Dyspepsia 30% of patients have delayed gastric emptying 10% have accelerated gastric emptying 40% have impaired gastric accommodation 30% have evidence of hypersensitivity to gastric distention Tack J. Curr Opin Gastroenterol 2011; 27: Bredenoord AJ. Clin Gastroenterol Hepatol 2003;1:264 72
6 Colonic Transit Time in IBS Simren M. Am J Gastroenterol 2012; 107: Small Intestinal Bacterial Overgrowth (SIBO) Defined as 10 5 or more colony-forming units of colonic bacteria per milliliter Upper small intestinal tract is relatively sterile environment Normal peristalsis Antibacterial action of gastric acid Diarrhea, constipation, bloating, gas, abdominal pain, B12 deficiency
7 IBS and SIBO overlap 78% (157/202) of IBS patients were positive for SIBO by lactulose breath test 47 patients were retested after abx rx 25/47 had eradication of SIBO 48% of eradicated group no longer met IBS criteria Pimentel, M. Am J Gastro. 2000;95: IBS pts and 26 controls Posserud. Gut. 2007;56:
8 IBS and SIBO overlap 4% IBS were found to have SIBO by jejunal cultures Similar proportions of positive LHBT and GHBT in IBS vs control Did not confirm strong association between IBS and SIBO Posserud. Gut. 2007;56: New Diagnostic Tests FD and IBS Disordered motility leading to altered transit and altered stool form Transit studies Altered intestinal microbiota Hydrogen breath test
9 Wireless Motility Capsule : SmartPill FDA approved ingestible capsule using sensor technology to evaluate GI motility Receiver Display software Wireless Motility Capsule : SmartPill Senses and measures temperature, ph and pressure Wirelessly transmits data to receiver Battery life 5+ days 26 mm x 13 mm TRANSMITTER PRESSURE SENSOR BATTERIES ph SENSOR MICROPROCESSOR
10 Overnight fast Patient Information List of medications to avoid Ingests 260 kcal SmartBar and then SmartPill Wears data receiver and goes about normal daily activities Return data receiver 3-5 days later Medications that alter ph Proton pump inhibitors Histamine receptor antagonist Antacids Medications that alter motility Prokinetics (metoclopromide, domperidone, erythromycin, azithromycin) Antiemetics Anticholinergics (dicyclomine, hyoscyamine) Laxatives Antidiarrheals Narcotics NSAIDS Time period of medication discontinuation 7 days 3 days 1 day Time period of medication discontinuation 3 days 3 days 3 days 2 days 3 days 3 days 3 days
11 Contraindications Dysphagia Suspected strictures or fistulae Pseudo-obstruction, ileus, gastric bezoar GI surgery within the past 3 months Diverticulitis Electromechanical medical device Pacemaker or infusion pump Not approved in children Wireless Motility Capsule Tracing Gastric Transit Small Bowel Transit Colonic Transit ph Temperature Pressure
12 Gastric Emptying Time (GET) GET : abrupt rise in ph (3 ph units) Validation of Gastric Emptying Time 87 healthy adults and 61 gastroparesis Simultaneous WMC & gastric emptying scintigraphy Sensitivity Specificity GES 2 h 34% 93% GES 4 h 44% 93% GET 65% 87% Kuo B, et al. Aliment Pharmacol Ther. 2008; 27:
13 Small Bowel Emptying Time (SBTT) SBTT : sustained (>10 minutes) drop in ph (1 ph unit) 10 healthy adults Validation of SBTT Simultaneous WMC and whole gut scintigraphy Comparable SBTT between 2 methods There are no prospective studies SBTT in diseased states intestinal pseudo obstruction Maqbool S et al. Dig Dis Sci. 2009l54:
14 Colonic Transit Time (CTT) CTT : loss of recording signal or abrupt decrease in temperature Validation for CTT 78 adults Rome II functional constipation and 87 healthy adults WMC vs 2 day and 5 day ROM Sensitivity Specificity SmartPill CTT 46% 95% WGTT 42% 95% Day 5 ROM 37% 95% Rao SS et al. Clin Gastro Heaptol. 2009;7:
15 Delayed Gastric and Colonic Transit
16 Hydrogen Breath Test Breath tests based on bacterial production of hydrogen and methane after metabolizing substrate Lactulose Glucose Xylose Breath Tests Hydrogen and Methane gas measured every 30 minutes for 3 hours Rise of Hydrogen 12 or 20 ppm above baseline is considered diagnostic Rise of Methane 20 ppm above baseline Wide variation in sensitivity and specificity
17 Lactulose Breath Test Lactulose not absorbed by small intestine Cleaved by bacteria in proximal colon into hydrogen In bacterial overgrowth, early hydrogen peak is observed min Double peak Slow and rapid small intestinal transit may affect test results Lactulose accelerates transit Sensitivity of 68% and specificity of 44% Kassinen A. Gastroenterology 2007;133:24e33. Simren M. Gut 2013;62:
18 Glucose Breath Test Normally glucose is entirely absorbed in proximal jejunum In bacterial overgrowth, glucose cleaved into carbon dioxide and hydrogen If positive, most likely SIBO If negative, may be missing distal SIBO Largest study, sensitivity of 62% and specificity of 83% Treatment
19 New Treatments FD Buspirone (5-HT 1A agonist) Superior to placebo in alleviating symptoms Early satiation, postprandial fullness and upper abdominal bloating Symptom improvement was associated with delay in liquid gastric emptying rate and an increase in meal-induced gastric accommodation Tandospirone (5-HT 1A agonist) Study in Japan Tack J. Clin Gastro and Hep 2012;10: Miwa H. Am J Gastroenterol 2009;104: Buspirone Tack J. Clin Gastro and Hep 2012;10:
20 Tack J. Clin Gastro and Hep 2012;10: New treatments for FD Acotiamide (Z-338) Enhances acetylcholine release via antagonism of the M1 and M2 muscarinic receptors Enhance gastric accommodation in animal studies Indirect effect on brain gut axis Does not prolong QT interval Suzuki H, Hibi T. Neurogastroenterol Motil 2010; 22: Tack J, Janssen P. Expert Opin Investig Drugs 2011; 20: Matsueda K. Gut Jun;61(6):821-8
21 Acotiamide 4-week placebo-controlled Phase III study in PDS in Japan Relieving postprandial fullness, early satiation and upper abdominal bloating Matsueda K. Gut Jun;61(6):821-8 Acotiamide : Overall Treatment Efficacy (OTE) Matsueda K. Gut Jun;61(6):821-8
22 Linaclotide Chey WD. Am J Gastroenterol. 2012
23 Linaclotide IBS C : 290 mcg daily 30 minutes prior to first meal CIC : 145 mcg daily 30 minutes prior to first meal Capsules should be swallowed whole and should not be broken apart or chewed Diarrhea was the most common (20%) adverse reaction TARGET I & TARGET II Multi-center, Phase III RCT. Enrolled 1260 non-c IBS patients Demographic data: mean age 45, 75% women, 90% white, 10% >65 yo Pimentel M. N Engl J Med (1):22-32
24 Study Design Rifaximin 550 mg TID vs Placebo for 14 days Follow up for 10 weeks Primary endpoint adequate relief of IBS symptoms Secondary endpoint adequate relief of bloating Pimentel M. N Engl J Med (1):22-32 Results p = p = p = Percent Responders Pimentel M. N Engl J Med (1):22-32
25 Overall improvement of global IBS symptoms with Rifaximin during 10 weeks of follow up Pimentel M. N Engl J Med (1):22-32 Mechanism of Action Reduction of overall bacterial load Decreased bacterial fermentation Less bloating Effect on intestinal microbiota might alter local mucosal engagement of bacteria such as the immune response of host Not FDA approved for the treatment of IBS
26 Modulation of Intestinal Microbiota A short course of non-absorbable antibiotic such as Rifaximin in IBS-D Improves bloating and flatulence Majority of trials of probiotics in IBS show some degree of efficacy Prebiotics and synbiotics should theoretically have the potential in treating FGD FODMAP Fermentable oligosaccharides, disaccharides, monosaccharides and polyols Poorly absorbed, shortchain carbohydrates, highly fermentable in presence of gut bacteria
27 FODMAP Fructans and Galactans Fructose Lactose Fructooligosaccharide Galactooligosaccharide Polyols Sorbitol Xylitol Mannitol Maltitol
28 FODMAP 26 Australian IBS pts with positive fructose breath tests Provided low FODMAP diet up to 22 wks Randomized 4 groups Fructose, fructan, fructose and fructan and glucose powder mixed in water Primary end point was were symptoms adequately controlled during the phase Shepherd SJ, Clin Gastro Hep, 2008:6; FODMAP Shepherd SJ, Clin Gastro Hep, 2008:6;
29 FODMAP : Practical Guidelines Hydrogen breath testing if readily available as this could potentially limit what foods need to be restricted. Referral to a dietitian who is comfortable with the low FODMAP approach Complete FODMAP restriction for 6 weeks. A slow controlled reintroduction of FODMAPs to determine the level that will be tolerated Summary Newer diagnostic tests Wireless motility capsule Hydrogen breath test Newer treatments for functional dyspepsia Buspirone, Tandospirone Acotiamide Newer treatments for IBS Linaclotide Rifaximin Probiotics Low FODMAP diet
Outline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationDiagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider
Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider Elizabeth Coss, MD General Gastroenterologist Audie Murphy Veterans Hospital UT Health This presentation does not
More informationNumber of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI
Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review
More informationThe long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome Dr Miranda Lomer RD Email: miranda.lomer@kcl.ac.uk What is IBS - ROME IV Criteria A functional bowel disorder in which
More informationOur evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders.
Our evidence. Your expertise. SmartPill : The data you need to evaluate motility disorders. SmartPill benefits your practice: Convenient performed right in your office Test standardization Provides direct
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationFunctional Heartburn and Dyspepsia
Functional Heartburn and Dyspepsia Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina Objectives Understand the means of diagnosing functional heartburn
More informationLow FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015
Low FODMAP Dietary Approach For FGD/IBS Our Experience Charlotte McCamphill 19 th February 2015 CONTENTS What Is IBS What are FODMAPs Service Provision Audit Results Future Work WHAT IS IBS The Rome III
More informationIBS The Physiologist s Perspective
IBS The Physiologist s Perspective Dr Anthony R. Hobson PhD Consultant Clinical Scientist, London The Functional Gut Clinic Reclaiming the F word The f-word functional has become a by-word for failure
More informationSIBO
SIBO What is it? Small Intestinal Bowel Overgrowth A chronic bacterial infection of the small intestine Caused by bad bacteria such as E Coli and Clostridium migrating to the small intestine There is not
More informationPrimary Management of Irritable Bowel Syndrome
Primary Management of Irritable Bowel Syndrome Jasmine Zia, MD Acting Instructor, Division of Gastroenterology Current Concepts in Drug Therapy CME Course April 23, 2015 Irritable Bowel Syndrome (IBS)
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Irritable bowel syndrome (IBS) has a variety of symptoms, most commonly cramping, abdominal pain, bloating, constipation, and diarrhea. Symptoms can vary from person to person,
More informationGut microbiota in IBS and its modification by diet: probiotics, prebiotics and low FODMAP diet
Gut microbiota in IBS and its modification by diet: probiotics, prebiotics and low FODMAP diet Kevin Whelan PhD RD FBDA Professor of Dietetics Department of Nutritional Sciences King s College London Nutritional
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationDefinition, Pathogenesis, and Management of That Cursed Dyspepsia
Clinical Gastroenterology and Hepatology 2018;16:467 479 Definition, Pathogenesis, and Management of That Cursed Dyspepsia Pramoda Koduru, Malcolm Irani, and Eamonn M. M. Quigley IM F1 김영기 Dyspepsia Umbrella
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationReal World Efficacy and Tolerability of Acotiamide in Relieving Multiple and Overlapping Symptoms in Patients of Functional Dyspepsia
Archives of Gastroenterology and Hepatology Volume 1, Issue 1, 2018, PP: 1-6 Real World Efficacy and Tolerability of Acotiamide in Relieving Multiple and Overlapping Symptoms in Varsha Narayanan 1 *, Shailesh
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationThe relationship between FODMAP intake and acute gastrointestinal symptoms in adults with IBS A novel analysis using the FAST Diary
The relationship between FODMAP intake and acute gastrointestinal symptoms in adults with IBS A novel analysis using the FAST Diary Macintosh A 1, Wright-McNaughton M 1, Frampton C 2, Skidmore P 1, Gearry
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationHompes Method. Practitioner Training Level II. Lesson Eight Part 1C SIBO Protocols
Hompes Method Practitioner Training Level II Lesson Eight Part 1C SIBO Protocols Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of Health For The People
More informationManagement of Functional Bowel Disorders
Management of Functional Bowel Disorders Amy Foxx-Orenstein, DO, FACG, FACP Professor of Medicine Mayo Clinic Tucson Osteopathic Medical Foundation May 1, 2016 Objectives Review epidemiology and pathophysiology
More informationCHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University
CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University 1 Definition of FGID Chronic and recurrent symptoms of the gastrointestinal
More informationWilliam D. Chey, MD Professor of Medicine University of Michigan
Evidence-based Treatment Strategies for IBS William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria for IBS Recurrent abdominal pain or discomfort at least 3 days / month in
More informationFood Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence
Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence Maria Vazquez Roque, MD, MSc Assistant Professor Gastroenterology and Hepatology 2010 MFMER slide-1 Objectives Gluten-free
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationAn Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome
An Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome American College of Gastroenterology August 2014, Indianapolis Brian E. Lacy, Ph.D., M.D. Professor of Medicine, Geisel School
More informationWhat is Irritable Bowel Syndrome (IBS)?
What is Irritable Bowel Syndrome (IBS)? Irritable bowel syndrome (IBS) is a health issue found in your intestines (gut). IBS can cause symptoms such as: Belly pain. Cramping. Gas. Bloating (or swelling)
More informationAnnouncing SIBO Testing Updates for February 2018
Announcing SIBO Testing Updates for February 208 Dear Valued Client, In the spirit of continuous improvement and updating our testing services with the most current science and research, BioHealth is aligning
More informationSUPPLEMENTARY INFORMATION Associated with
Table1: Rome III and Rome IV diagnostic criteria for IBS, functional constipation and functional dyspepsia. Rome III diagnostic criteria 1,2 Rome IV diagnostic criteria 3,4 Diagnostic criteria for IBS
More informationThe PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures
The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off
More informationGrigoris Leontiadis, MD PhD. McMaster University Upper Gastrointestinal and Pancreatic Diseases Cochrane Group
Grigoris Leontiadis, MD PhD McMaster University Upper Gastrointestinal and Pancreatic Diseases Cochrane Group No relevant financial relationships with any commercial interests CDDW/CASL Meeting Session:
More informationManagement of Functional Dyspepsia (FD)
Management of Functional Dyspepsia (FD) Amy S. Oxentenko, MD, FACG Program Director and Associate Chair, IM Associate Professor of Medicine Mayo Clinic, Rochester Outline Define functional dyspepsia (FD)
More informationpissn: eissn: Journal of Neurogastroenterology and Motility
JNM J Neurogastroenterol Motil, Vol. 20 No. 3 July, 2014 pissn: 2093-0879 eissn: 2093-0887 http://dx.doi.org/10.5056/jnm14022 Original Article Effects of Chili Treatment on Gastrointestinal and Rectal
More informationGASTROPARESIS. C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis
GASTROPARESIS C. Prakash Gyawali, MD Professor of Medicine Washington University in St. Louis Symptom Definitions Nausea: a subjective feeling of wanting to vomit Vomiting: forceful expulsion of gastroduodenal
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationIrritable bowel syndrome (IBS) is a functional gastrointestinal. Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome INTRODUCTION
Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome by Mark Pimentel Although several pathophysiologic models have been suggested, the etiology of irritable bowel syndrome (IBS) is unknown.
More informationRome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC
Rome III Criteria for IBS Irritable Bowel Syndrome: What s the Latest? Tim Burke, DO Pacific Digestive Associates Clackamas, OR Recurrent abdominal pain or discomfort at least 3 days/month in the last
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationWilliam D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology
Dietary and Other Non-pharmacological Management of IBS William D. Chey, MD, FACG Nostrant Professor of Medicine Director GI Nutrition Program University of Michigan Peter Loftus, May 2, 2016 Page 1 of
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationWhat s the Latest? Rome III Criteria for IBS
Irritable Bowel lsyndrome: What s the Latest? American College of Gastroenterology Las Vegas, January 2014 Bi Brian E. Lacy, Ph.D., PhD M.D., MD FACG Professor of Medicine Geisel School of Medicine at
More informationFODMAPs: Emerging Science and Implications for Practice
FODMAPs: Emerging Science and Implications for Practice Megan Rossi, PhD RD @DrMegan_RD @Dr_Megan www.drmeganrossi.com BDA guidelines for dietary management of IBS 1) Healthy eating and lifestyle Alcohol
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More information... SELECTED ABSTRACTS...
... SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on irritable bowel syndrome, were selected for their relevance to this supplement. A Technical Review for
More informationThe Roadmap to FODMAP
The Roadmap to FODMAP Food Intolerance and Sugar Malabsorption in Chronic Abdominal Pain Food The Good the Bad and the Ugly April 2017 Pediatrics Disclosure I have the following financial relationships
More informationAPDW 2016 Poster No. a90312
APDW 2016 Poster No. a90312 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients with IBS-C Results of a multi-center,
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Irritable Bowel Syndrome Jeffrey Jump, MD CHI Memorial Integrative Medicine Associates Jeffrey_jump@memorial.org Chronic abdominal pain and altered bowel function in the absence
More informationAmyloidosis & the GI Tract
Amyloidosis & the GI Tract John O. Clarke, M.D. Director, Esophageal Program Clinical Associate Professor of Medicine Stanford University john.clarke@stanford.edu 2017 Topics to cover 1) Patterns of GI
More informationWhole Health in Your Practice - Applying CIH March Whole Health in Your Practice 14. APPLYING CIH. Lucky Sarah VETERANS HEALTH ADMINISTRATION
Whole Health in Your Practice 14. APPLYING CIH Lucky Sarah 1 Not-so-lucky Joe Joe - GI 31 yo Diarrhea predominant IBS after being treated for a GI infection during a tour in Iraq Symptoms: Bloating and
More informationIrritable Bowel Syndrome
Irritable Bowel Syndrome Functional gastrointestinal disorders Definition A variable combination of chronic or recurrent gastrointestinal symptoms (attributed to the pharynx, esophagus, stomach, biliary
More informationEvolving Therapy in Irritable Bowel Syndrome (IBS)
Evolving Therapy in Irritable Bowel Syndrome (IBS) Dr. Syed Mohammad Arif MBBS, FCPS (Medicine), MD (Gastro) Associate Professor Department of Medicine Dhaka Medical College A good set of bowels is worth
More informationWhat Is the Low-FODMAP Diet?
LOW-FODMAP DIET What Is the Low-FODMAP Diet? FODMAP refers to a group of five sugars found in certain foods. These sugars are lactose, fructose (in excess), fructans, galactans and polyols. Specifically,
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationGluten Free Alphabet Soup!
Gluten Free Alphabet Soup! Kate Scarlata, RDN, LDN Owner, For a Digestive Peace of Mind Digestive Health Nutrition Consulting Medway, MA DISCLOSERS Advisor and consultant Nestle Health Science, FODY foods,
More informationNicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia
More informationPresenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018
Presenter Irritable Bowel Syndrome Current evidence for diagnosis & management Julie Daniels DNP, CNM Assistant Professor Course Coordinator of Primary Care of Women Faculty at Frontier Nursing University
More informationTreatment of IBS - Diet or Drugs?
Treatment of IBS - Diet or Drugs? Brooks D. Cash, MD, FACG Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Learning objectives Review the evolving
More informationIBS-D: What to Do When Typical Treatment Methods Fail
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationInflammatory or Irritable? (the bowel, not the speaker)
South GP CME Edgar Centre, Dunedin August 2014 Inflammatory or Irritable? (the bowel, not the speaker) Dr Jason Hill MBChB FRACP FRCP Edin Department of Gastroenterology, Southern DHB Dunedin School Of
More informationROME IV CRITERIA FOR IBS
PRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF IBS BRENDA HORWITZ MD PROFESSOR OF CLINICAL MEDICINE LEWIS KATZ SCHOOL OF MEDICINE AND TEMPLE UNIVERSITY HEALTH SCIENCES CENTER OR THINGS I ALWAYS WANTED TO
More informationIrritable Bowel Syndrome
68 TH ANNUAL MCGILL REFRESHER COURSE FOR FAMILY PHYSICIANS 2017 Irritable Bowel Syndrome Gad Friedman, MDCM, FRCPC Jewish General Hospital DISCLOSURES I have no disclosures LEARNING OBJECTIVES 1. Review
More informationState of the Art: Management of Irritable Bowel Syndrome
ACG/FGS Annual Spring Symposium March 16-18, 2018 Bonita Springs, FL State of the Art: Management of Irritable Bowel Syndrome William D. Chey, MD Professor of Medicine University of Michigan IBS: Rome
More informationSmall Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results
Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results Martin Carr, M.D. March 3, 2018 Good evening everyone, this is Martin Carr, and I
More informationSlide #43. Disclosure of Financial Relationships. IBS: Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine
Disclosure of Financial Relationships : Is it in Your Head or Gut? Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Anthony Lembo,
More informationThe Role of Food in the Functional Gastrointestinal Disorders
The Role of Food in the Functional Gastrointestinal Disorders H. Vahedi, MD. Gastroentrologist Associate professor of medicine DDRI 92.4.27 vahedi@ams.ac.ir Disorder Sub-category A. Oesophageal disorders
More informationFODMAPs: Major role in food sensitivities
: Major role in food sensitivities Jessica Biesiekierski Post-doctoral Research Fellow Translational Research Center for Gastrointestinal Disorders KU Leuven, Belgium Role of food in GI symptoms? Abdominal
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationIJBPAS, December, 2014, 3(12): SMALL INTESTINE BACTERIAL OVERGROWTH IN IRANIAN IRRITABLE BOWEL SYNDROME PATIENTS
: 3041-3050 ISSN: 2277 4998 SMALL INTESTINE BACTERIAL OVERGROWTH IN IRANIAN IRRITABLE BOWEL SYNDROME PATIENTS RAHMATOLLAH RAFIEI 1, MITRA SHAVAKHI 2, LOOTFOLLAH FOULADI 3, MOHAMMAD ARASH RAMEZANI 4 AND
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationT H E B E T T E R H E A L T H N E W S
Dr. Paul G. Varnas & WholeHealthAmerica.com present V O L U M E 1 3, I S S U E 4 T H E B E T T E R H E A L T H N E W S A P R I L, 2 0 1 6 M O R E P R O B L E M S W I T H P R O T O N P U M P I N H I B I
More information10/1/2016. Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD. Kimberly Kearns, APN. Mary Davitt, PMHNP.
Kimberly Kearns, MS, APN, ANP-BC Mary Davitt, MS, PMHNP-BC Rachel Richardson, RD Kimberly Kearns, APN Speakers Bureau: Medtronic Salix Pharmaceuticals Takeda Pharmaceuticals Mary Davitt, PMHNP None Rachel
More informationOutcome of breath tests in adult patients with suspected small intestinal bacterial overgrowth
Gastroenterology and Hepatology From Bed to Bench. 207 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Outcome of breath tests in adult patients with suspected small
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationWhat s New in IBS with Diarrhea. Dr. Geoffrey K. Turnbull, MD April 6, 2018.
What s New in IBS with Diarrhea Dr. Geoffrey K. Turnbull, MD April 6, 2018. Objectives To learn how to diagnose IBS with particular emphasis on patients who have diarrhea predominantly. Review management
More informationIBS. Dan Carter, M.D. Institute of Gastroenterology Sheba medical center
IBS Dan Carter, M.D. Institute of Gastroenterology Sheba medical center Epidemiology Irritable bowel syndrome is a common functional gastrointestinal disorder that manifests as abdominal pain or discomfort
More informationDyspepsia: alarm symptoms, investigation and management
Drug review Dyspepsia Dyspepsia: alarm symptoms, investigation and management SPL Steven Fong MRCP and Jason Dunn PhD, MRCP Dyspepsia is a common symptom and the priority is to identify alarm signals that
More informationPharmacotherapy for IBS
Pharmacotherapy for IBS Brooks D. Cash, M.D., FACG Chief, Gastroenterology Professor of Medicine University of South Alabama Director, GI Physiology, USA Medical Center Mobile, AL Disclosures I have served
More informationTreatment of Bacterial Overgrowth in Patients With Irritable Bowel Syndrome
Treatment of Bacterial Overgrowth in Patients With Irritable Bowel Syndrome Background: Rifaximin is an effective treatment of irritable bowel syndrome (IBS) with small intestinal bacterial overgrowth
More information4) Irritable Bowel Syndrome - Dr. Shaikhani. Epidemiology. Pathophysiology. Burden. Diagnosis
4) Irritable Bowel Syndrome - Dr. Shaikhani Epidemiology A common disorder, with a 7% prevalence. Women are 1.5 times more likely to be affected than men, most commonly between ages 20-40 years. Onset
More informationBloating, Flatulence, and
A 45-Year-Old Man With Recurrent Abdominal Pain, Bloating, Flatulence, and Intermittent Loose Stools Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory
More informationRefractory IBS-D: An Evidence-Based Approach to Therapy
Refractory IBS-D: An Evidence-Based Approach to Therapy Darren M. Brenner, MD, AGAF Associate Professor of Medicine and Surgery Director, Northwestern Neurogastromotility, Functional, and Integrated Bowel
More informationBreath analysis a key to understanding intestinal function
45 Breath analysis a key to understanding intestinal function D. Tivey 1 and R. Butler 2 1 Department of Animal Science, Waite and Roseworthy Campuses, University of Adelaide, PMB1, Glen Osmond SA 564
More informationEvaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies
Neurogastroenterol Motil (2011) 23, 8 23 doi: 10.1111/j.1365-2982.2010.01612.x REVIEW ARTICLE Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology
More informationSmall Intestinal Bacterial Overgrowth in Patients with Refractory Functional Gastrointestinal Disorders
JNM J Neurogastroenterol Motil, Vol. 22 No. 1 January, 216 pissn: 293-879 eissn: 293-887 http://dx.doi.org/.6/jnm116 Original Article Small Intestinal Bacterial Overgrowth in Patients with Refractory Functional
More informationA Guide to Gastrointestinal Motility Disorders
A Guide to Gastrointestinal Motility Disorders Albert J. Bredenoord André Smout Jan Tack A Guide to Gastrointestinal Motility Disorders Albert J. Bredenoord Gastroenterology and Hepatology Academic Medical
More informationSmall-Bowel and colon Transit. Mahsa Sh.Nezami October 2016
Small-Bowel and colon Transit Mahsa Sh.Nezami October 2016 Dyspeptic symptoms related to dysmotility originating from the small bowel or colon usually include : Abdominal pain Diarrhea Constipation However,
More informationIrritable Bowel Disease. Dr. Alexandra Ilnyckyj MD
Irritable Bowel Disease Dr. Alexandra Ilnyckyj MD Exactly what is IBS? Common condition affecting mostly women Symptoms are variable but they reflect altered gut movement (motility) and sensation Commonly
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationNon-Invasive Assessment of Intestinal Function
Overview Non-Invasive Assessment of Intestinal Function Introduction This paper will demonstrate that the 13 C-sucrose breath test ( 13 C-SBT) determines the health and function of the small intestine.
More informationWhy does my stomach hurt? Exploring irritable bowel syndrome
Why does my stomach hurt? Exploring irritable bowel syndrome By Flavio M. Habal, MD, PhD, FRCPC Case In this article: 1. What is IBS? A 45-year-old female is referred to your office with recurrent 2. How
More informationManagement Challenges of the Gastrointestinal Tract (GIT) in Systemic Sclerosis (SSc) Presented by: Tracy M. Frech, MD, MS April 2016
Management Challenges of the Gastrointestinal Tract (GIT) in Systemic Sclerosis (SSc) Presented by: Tracy M. Frech, MD, MS April 2016 DISCLOSURES AND COPYRIGHT No financial or ethical conflicts of interest.
More informationObjectives. Pain Types Brief Review. Referred Pain. Chronic/Recurrent Abdominal Pain 1/12/2017. I have no conflicts of interest to disclose
Joshua D Noe, MD Associate Professor of Pediatric Gastroenterology Hepatology and Nutrition Medical College of Wisconsin I have no conflicts of interest to disclose Objectives Differentiate functional
More informationIRRITABLE BOWEL SYNDROME Dr E Lalor, MB ChB, FRCPC 2016 (but written before Rome IV see Gastroenterology, May 2016).
IRRITABLE BOWEL SYNDROME Dr E Lalor, MB ChB, FRCPC 2016 (but written before Rome IV see Gastroenterology, May 2016). Irritable bowel syndrome (IBS) is one of the functional GI (gastro-intestinal) disorders,
More informationGeographical and Cultural Food-related Symptoms, Food Avoidance and Elimination
Geographical and Cultural Food-related Symptoms, Food Avoidance and Elimination Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Digestive Health Center of Excellence University of Virginia Adverse Reactions
More information